Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,689 across all filing types
Latest filing 2021-04-22 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
2021年第一季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "迪瑞医疗科技股份有限公司 2021 年第一季度报告全文" which translates to "Dirui Medical Technology Co., Ltd. 2021 First Quarter Report Full Text." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow analysis, shareholder information, and management discussion of financial results for the first quarter of 2021. The presence of comprehensive financial statements and analysis for a quarterly period clearly indicates this is a quarterly financial report. The document length is about 15,000 characters, which is consistent with a full quarterly report rather than a brief announcement or summary. There is no indication that this is an announcement of a report or a certification letter. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-04-22 Chinese
2020年年度报告
Annual Report Classification · 100% confidence The document is titled "迪瑞医疗科技股份有限公司 2020 年年度报告全文" which translates to "Dirui Medical Technology Co., Ltd. 2020 Annual Report Full Text." It contains detailed sections including company overview, financial data for the year 2020, risk factors, business overview, financial indicators, and other comprehensive information typical of an annual report. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial data, management discussion, and detailed disclosures. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2021-04-22 Chinese
2020年年度报告摘要
Annual Report Classification · 95% confidence The document is titled "迪瑞医疗科技股份有限公司 2020 年年度报告摘要" which translates to "Dirui Medical Technology Co., Ltd. 2020 Annual Report Summary." It contains detailed financial data for the year 2020, including revenue, net profit, earnings per share, and asset information. It also discusses business operations, market analysis, R&D, internal governance, and changes in accounting policies. The document is over 11,000 characters, indicating it is a substantive report rather than a brief announcement. The content aligns with an official yearly report covering company activity and full financial performance, which fits the definition of an Annual Report (10-K). FY 2020
2021-04-22 Chinese
上海荣正投资咨询股份有限公司关于迪瑞医疗科技股份有限公司2021年限制性股票激励计划（草案）之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the "2021 Restricted Stock Incentive Plan" of a company. It contains detailed sections including definitions, statements, assumptions, main content of the incentive plan, financial advisor opinions, and legal and regulatory compliance checks. The content focuses on the stock incentive plan, its terms, conditions, eligibility, pricing, performance targets, and compliance with laws and regulations. It is a standalone report providing audit-like opinions and verification on the stock incentive plan, rather than a full annual or quarterly financial report. It is not a simple announcement or a brief summary but a detailed advisory report. This fits the category of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific plans or tests, excluding full annual reports. The document is about a financial advisory report on a stock incentive plan, which is a typical subject of an audit or advisory report rather than other categories like management changes, earnings releases, or investor presentations. FY 2021
2021-04-22 Chinese
2020年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as the 2020年度审计报告 (2020 Annual Audit Report) of 迪瑞医疗科技股份有限公司. It contains detailed audit opinions, audit basis, key audit matters, management responsibilities, and the auditor's responsibilities. It includes comprehensive financial statements such as consolidated balance sheet, income statement, cash flow statement, and changes in shareholders' equity, along with notes and attachments related to the audit. The presence of an independent auditor's report and detailed financial data confirms this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2020
2021-04-22 Chinese
独立董事述职报告（徐杉）
Board/Management Information Classification · 95% confidence The document is titled as the "2020年度独立董事述职报告" which translates to "2020 Annual Independent Director's Work Report." It details the independent director's attendance at board meetings, opinions on various company matters, committee work, and efforts to protect investor rights during the 2020 fiscal year. The content is a detailed report of the independent director's activities and responsibilities over the year, not an announcement or a brief summary. It does not contain financial statements or audit results but focuses on governance and director duties. This fits best under the category of Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities. The document length is 3440 characters, which is relatively short but contains substantive content about the director's role and opinions, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2021-04-22 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.